Learning Points
- Endometrioid ovarian carcinoma can arise in a background of
endometriosis.
- Carboplatin/Paclitaxel adjuvant chemotherapy has limited survival
benefit in low-grade endometrioid ovarian adenocarcinoma, a subtype of
ovarian cancer for which novel biomarker therapies are still being
developed.
- Maximal cytoreductive effort with the aim to achieve R0 is key to the
management of recurrent low-grade endometrioid ovarian cancer.
- Complex operations with multidisciplinary involvement may be required
in order to remove all macroscopic disease.